期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
乳腺癌患者新辅助化疗后病理完全缓解的相关影响因素分析及列线图预测模型的构建 被引量:9
1
作者 曲天宇 葛一涵 赵毅 《现代肿瘤医学》 CAS 北大核心 2021年第4期590-594,共5页
目的:建立关于乳腺癌新辅助化疗后病理完全缓解的综合预测模型,预测新辅助化疗后病理缓解,指导临床上诊疗方案的选择。方法:回顾分析2015年1月至2020年3月148例乳腺癌新辅助化疗患者的临床资料、化疗前核磁共振资料及病理资料,根据术后... 目的:建立关于乳腺癌新辅助化疗后病理完全缓解的综合预测模型,预测新辅助化疗后病理缓解,指导临床上诊疗方案的选择。方法:回顾分析2015年1月至2020年3月148例乳腺癌新辅助化疗患者的临床资料、化疗前核磁共振资料及病理资料,根据术后病理分为pCR组与npCR组。采用χ~2检验对两组指标先行单因素分析;将P<0.05的指标及考虑可能有临床意义的指标纳入多因素Logistic回归分析。应用多因素分析考虑有统计学意义(P<0.05)及临床意义的指标构建乳腺癌新辅助化疗后病理缓解综合预测模型的列线图,并运用ROC曲线评价此模型的效能。结果:单因素分析表明腺体背景强化类型、最长径、病理分型对乳腺癌是否达到病理完全缓解具有预测作用;多因素分析表明,腺体背景强化类型、最长径、病理分型均是新辅助化疗后病理完全缓解的独立预测因素(P<0.05)。乳腺癌新辅助化疗后病理缓解的预测模型的曲线下面积为0.769,特异度为65.5%,敏感度为78.9%。结论:乳腺癌新辅助化疗后病理完全缓解的综合预测模型对病理缓解状态有较好的预测能力,此模型可为乳腺癌新辅助化疗后患者选择手术方式提供参考。 展开更多
关键词 乳腺癌新辅助化 病理完全缓解 列线图
下载PDF
Investigation of the Effect of Neoadjuvant Chemotherapy on Stage Ⅱ Breast Cancer
2
作者 Yanli Song Dong Wang 《Chinese Journal of Clinical Oncology》 CSCD 2007年第2期142-144,共3页
OBJECTIVE To investigate the effect of neoadjuvant chemotherapy in treatment of Stage Ⅱ breast cancer. METHODS The data from 113 patients with breast cancer of the same pathologic type in Stage Ⅱ,during the period o... OBJECTIVE To investigate the effect of neoadjuvant chemotherapy in treatment of Stage Ⅱ breast cancer. METHODS The data from 113 patients with breast cancer of the same pathologic type in Stage Ⅱ,during the period of 1995 to 2001,were analyzed retrospectively.Among the patients,47 were treated with neoadjuvant chemotherapy,and 66 received no adjuvant therapy before surgery(control group).After the patients of the neoadjuvant chemotherapy group had received 2 courses of chemotherapy with the CMF regimen,the surgical procedure was conducted. RESULTS Complete remission(CR)was attained in 9 of the 47 cases receiving neoadjuvant chemotherapy and partial remission(PR)was reached for 22 cases.The rate of breast-conserving surgery was enhanced from 22.73%to 46.81%(P〈0.05)in the neoadjuvant treatment group. There was no difference in the 5-year overall survival(OS)and disease-free survival(DFS)rate between the two groups(P〉0.05),but the 5-year OS and DFS of the cases with clinical tumor remission was higher compared to the control group(P〈0.05). CONCLUSION Neoadjuvant chemotherapy can enhance the rate of breast conservation for Stage Ⅱ breast cancer and may improve the prognosis of the cases with clinical remission. 展开更多
关键词 breast cancer neoadjuvant chemotherapy five-year survival rate.
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部